Sesame Review: Marketplace Model, Experience, Trade-offs

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — evidence-based guidance on GLP-1 therapies, weight management protocols, and the genetic variables that shape every metabolic decision. Browse all Peptides & GLP-1 education

This is an independent editorial review. PlexusDx has no commercial relationship with Sesame or its parent company, and no affiliate links or compensation are involved.

A useful review balances what a program does well against where it asks the buyer to do the homework. This editorial assessment of Sesame, current as of April 2026, looks at its market positioning, the typical patient experience, the trade-offs of its model, and the reputation factor no review can measure for you.

Sesame's positioning in the market

Sesame (Sesame Care) positions itself as marketplace telehealth — a platform connecting patients to independently listed providers rather than a vertically integrated weight clinic. In the GLP-1 category that positioning is a genuine differentiator: it can widen provider choice and price visibility, while placing more of the comparison work on the patient. Judging it fairly means holding both sides of that trade at once. A marketplace and a managed clinic can quote similar prices while delivering very different experiences.

How the patient experience typically unfolds

The path mirrors most telehealth GLP-1 programs: an intake form covering weight, medical history, and current medications; a licensed clinician's review and, if eligibility is met, a prescription; routing to a retail pharmacy for FDA-approved brand products or a 503A compounding pharmacy for compounded semaglutide or tirzepatide; and ongoing follow-up for titration and side effects. Details such as provider type and pharmacy partner vary, so review current specifics before enrolling. Knowing the sequence in advance makes it easier to spot where a particular program adds value or quietly leaves gaps. Documenting each step as you go makes an unfamiliar process far easier to evaluate. See Sesame's official website.

Strengths and trade-offs of the marketplace model

The strengths are choice and transparency of listed pricing. The trade-offs are continuity and consistency: with independently listed providers, the experience can vary more than at a single-brand clinic, and bundling of follow-up differs by listing. Neither is a verdict on its own — a marketplace suits a self-directed buyer, while someone wanting a single managed relationship may prefer a different structure. The honest summary is that the model optimizes for flexibility and price visibility rather than a single continuous care relationship.

The clinical foundation shared across GLP-1 programs

Any review should anchor on the pharmacology, which is identical regardless of platform: GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and GIP/GLP-1 dual agonists (tirzepatide). The evidence rests on STEP (semaglutide, NEJM 2021), SURMOUNT (tirzepatide, NEJM 2022), and SURMOUNT-OSA (tirzepatide, NEJM 2024). Trial populations and endpoints differ, and outcomes vary from person to person. Anchoring on that shared science keeps a review focused on service and sourcing, which is where programs actually diverge. Reviews that skip the pharmacology risk overstating differences that are really about branding.

The reputation factor no review captures: your genetics

No review of a program can tell you how your own biology will meet a GLP-1 compound. Variants in FTO, GLP1R, MC4R, and TCF7L2 describe the metabolic terrain any compound acts on. The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights. It does not predict response and never reads drug response; it supplies the one input a program review structurally cannot. Not affiliated: PlexusDx has no commercial relationship with Sesame.

PlexusDx offers semaglutide and tirzepatide through its Weight Management Protocols, paired with that upstream genetic context. That context is the piece a program review cannot supply, because it depends on you rather than the platform.

Related reading on PlexusDx: What Is GLP 1, GLP 1 What Is, GLP 1 Receptor Agonist, GLP 1 Drugs.

Frequently Asked Questions

What is the overall take on Sesame?

Sesame is a marketplace telehealth platform whose strengths are provider choice and listed-price visibility, with the trade-off that continuity and bundled follow-up can vary. It suits a self-directed buyer comfortable comparing listings. As with any program, confirm current details on the provider's own site before deciding.

What does the patient experience look like?

Expect an intake form, a licensed clinician's review, a prescription routed to a retail or 503A compounding pharmacy, and ongoing follow-up for titration and side effects. The pattern mirrors most telehealth GLP-1 programs, though provider type and pharmacy partner differ, so review the specifics before committing.

What are the main trade-offs to weigh?

The marketplace model trades single-clinic continuity for wider provider choice and price transparency. Follow-up bundling varies by listing. Whether that is a strength or a drawback depends on how much managed, consistent support you want versus flexibility to compare and choose among independent providers.

What can a review not tell me?

No review can predict how your biology will respond to a GLP-1 compound. The Precision Peptide Genetic Test reads pathway variants in FTO and MC4R, and TCF7L2 for upstream context — it never predicts drug response. Pair that context with a conversation with a qualified healthcare provider.

This article is part of the PlexusDx Education Hub. Browse all Peptides & GLP-1 education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.